ИССЛЕДОВАНИЕ ЭФФЕКТИВНОСТИИ БЕЗОПАСНОСТИ ТЕРАПИИ ТЕРИПАРАТИДОМ(ФОРСТЕО) В ТЕЧЕНИЕ 1 ГОДА ПРИ ПОСТМЕНОПАУЗАЛЬНОМОСТЕОПОРОЗЕ
https://doi.org/10.14341/osteo200626-12
Аннотация
Об авторах
L ROZhINSKAYaS ARAPOVA
L DZERANOVA
N MOLITVOSLOVOVA
A IL'IN
N SAZONOVA
T ChERNOVA
A ShIShKINA
I DEDOV
L BENEVOLENSKAYa
O NIKITINSKAYa
T KOROTKOVA
N TOROPTsOVA
A SMIRNOV
N DEMIN
V NIKOLENKO
L BRIZhAN'
L TsIBINA
Список литературы
1. Торопцова Н.В., Беневоленская Л.И. Уровень витамина D в сыворотке крови у женщин в постменопаузе. Тезисы 2 Российского конгресса по остеопорозу. Ярославль, 28 сентября - 1 октября 2005г., Ярославль, «Литера». С. 44-45.
2. Balena R., Toolan B.C., Shea M., Markatos A., Myers E.R., Lee S.C., Opas E.E., Seedor J.G., Klein H., Frankenfield D.: The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone hystomorphometry and bone strength in ovariectomized nonhuman primates. J. Clinical Investigation 1993 Vol. 92 pp. 2577-2586.
3. Black D., Cummings S., Karpf D., Cauley J.A., Thompson D.E., Nevitt M.C., Bauer D.C., Genant H.K., Haskell W.L., Marcus R., Ott S.M., Torner J.C., Quandt S.A., Reiss T.F., Ensrud K.E.: Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. J. Lancet 1996 Vol. 348 pp. 1535-1541.
4. Burr D.B., Hirano T., Turner C.H., Hotchkiss C., Brommage R., Hock J.M.: Intermittently administered human parathyroid hormone (1-34) treatment increases intracortical bone turnover and porosity without reducing bone strength in the humerus of ovariectomized cynomolgus monkeys. J. Bone Mineral Research 2001 Vol. 16 pp. 157-165.
5. Cosman F., Nieves J., Woelfert L. et al. Parathyroid responsivity in postmenopausal women with osteoporosis during treatment with parathyroid hormone. J Clin Endocrinol Metab 1998; 83: 788-790, 33.
6. Cosman F., Nieves J., Woelfert L., Formica C., Gordon S., Shen V., Lindsay R.: Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal. J. Bone and Mineral Research 2001 Vol. 16 pp.925-931.
7. Dempster D.W., Cosman F., Kurland E.S., Zhou H., Nieves J., Woelfert L., Shane E., Plavetic K., Muller R., Bilezikian J., Lindsay R.: Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study. J. Bone and Mineral Research 2001 Vol. 16 pp. 1846-1853.
8. Draper M.W., Flowers D.E., Huster M..W., Neild J.A., Harper K.D., Arnaud C.: A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J. Bone Mineral Research 1996 Vol. 11, pp. 835-842.
9. Ebeling P.R., Russel R.G.G.: Teriparatide (rhPTH 1-34) for the treatment of osteoporosis. / International J. Clinical Practice 2003 Vol. 57 pp. 710-718.
10. Finkelstein J.S., Klibanski A., Arnold A.L., Toth T.L., Hornstein M.D., Neer R.M.: Prevention of estrogen deficiency-related bone loss with human parathyroid hormone-(1-34): a randomized controlled trial. JAMA. 1998 Vol. 280 pp. 1067-1073.
11. Fujita T., Inoue T., Morii H., Morita R., Norimatsu H., Orimo H., Takahashi H.E., Yamamoto K., Fukunaga M.: Effect of an intermittent weekly dose of human parathyroid hormone (1-34) on osteoporosis: a randomized double-masked prospective study using three dose levels. J. Osteoporosis Internal 1999 Vol. 9 pp. 296-306.
12. Gallagher J.C. et al. (Semparatide Investigators). PTHrP (1-34) analog, semparatide acetate (RS-66271) causes sustained increases BMD in spine in postmenopausal osteoporotic women: two randomised placebo-controlled trials. Program and abstract of the J. Bone and Miner. Res. Annual Meeting.September 30-Ortober 4 1999; St.Louis, Mo. Abstr. 1018.
13. Genant H.K., Wu C., van Kuijk et al. Vertebral fracture assessment using a semiquantitatove technique. 1993, JBMR., v.8, No 9, p.1137-1148.
14. Jiang Y., Zhao J.J., Mitlak B.H., Wang O., Genant H.K., Eriksen E.F.: Recombinant human Parathyroid hormone (1-34) [Teriparatide] improves both cortical and cancellous bone structure. J. Bone and Mineral Research 2003 Vol. 18 pp. 1932-1941.
15. Kleerekoper M., Nelson D.A., Peterson EL Flynn MJ., Pawluszka AS., Jacobsen G., Wilson P.: Reference data for bone mass, calciotropic hormones, and biochemical markers of bone remodeling in older (55- 75) postmenopausal white and black women. J. Bone Mineral Research 1994 Vol. 9 pp. 1267-1276.
16. Marcus R., Wang O., Satterwhite J., Mitlak B.: The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis. J. Bone Mineral Research. 2003 Vol.18 pp.18-23. Neer R.M., Arnaud C.D., Zanchetta J.R., Prince R., Gaich G.A.,
17. Reginster J.Y., Hodsman A.B., Eriksen E.F., Ish-Shalom S., Genant H.K., Wang O., Mitlak B.H.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. England J. Medicine 2001 Vol.35 pp. 1434-1441.
18. Orwoll E.S., Scheele W.H., Paul S., Adami S., Syversen U., Diez-Perez A., Kaufman J.M., Clancy A.D., Gaich G.A.: The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J. Bone Mineral Research 2003 Vol.18 pp. 9-17.
19. Rosen C.J., Bilezikian J.P. Clinical review 123: Anabolic therapy for osteoporosis. J Clin Endocrinol Metab 2001; 86:957-964.
20. Thamsborg G., Jensen J.E., Kollerup G., Hauge E.M., Melsen F., Snirensen O.H.: Effect of nasal salmon calcitonin on bone remodeling and bone mass in postmenopausal osteoporosis. J. Bone 1996 Vol. 18 pp. 207-212.
21. Wronski T.J., Clintron M., Doherty A.L., Dann L.M.: Estrogen treatment prevent osteopenia and depresses bone turnover in ovariectomized rats. J. Endocrinology 1988, Vol. 123 pp. 681-686.
Рецензия
Для цитирования:
., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., ., . ИССЛЕДОВАНИЕ ЭФФЕКТИВНОСТИИ БЕЗОПАСНОСТИ ТЕРАПИИ ТЕРИПАРАТИДОМ(ФОРСТЕО) В ТЕЧЕНИЕ 1 ГОДА ПРИ ПОСТМЕНОПАУЗАЛЬНОМОСТЕОПОРОЗЕ. Остеопороз и остеопатии. 2006;9(2):6-12. https://doi.org/10.14341/osteo200626-12
For citation:
ROZhINSKAYa L.Y., ARAPOVA S.D., DZERANOVA L.K., MOLITVOSLOVOVA N.N., IL'IN A.V., SAZONOVA N.I., ChERNOVA T.O., ShIShKINA A.A., DEDOV I.I., BENEVOLENSKAYa L.I., NIKITINSKAYa O.A., KOROTKOVA T.A., TOROPTsOVA N.V., SMIRNOV A.V., DEMIN N.V., NIKOLENKO V.K., BRIZhAN' L.K., TsIBINA L.V. ISSLEDOVANIE EFFEKTIVNOSTII BEZOPASNOSTI TERAPII TERIPARATIDOM(FORSTEO) V TEChENIE 1 GODA PRI POSTMENOPAUZAL'NOMOSTEOPOROZE. Osteoporosis and Bone Diseases. 2006;9(2):6-12. (In Russ.) https://doi.org/10.14341/osteo200626-12
Просмотров: 271
Контент доступен под лицензией Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Послать статью по эл. почте 
